The St. Jude Children's Research Hospital Comprehensive Cancer Center (SJCCC) Clinical Trials Scientific Review Committee (CT-SRC) serves as the internal, expert body responsible for reviewing the scientific rationale, feasibility, and study design of all clinical research protocols opened within the SJCCC. As an additional and related function, the CT-SRC monitors the progress of all SJCCC protocols, ensuring that they adhere to the approved study design;achieve their accrual goals in a timely manner;adhere to approved stopping criteria;and that patient safety is maintained. The CT-SRC has the authority to recommend protocol modifications and to close studies. The CT-SRC works in close collaboration with the other clinical trials oversight committees within the SJCCC including the IRB. Together, these complementary but non-overlapping bodies ensure the appropriate and safe conduct of high-quality clinical research within the SJCCC. Administratively, the CT-SRC is coordinated through the Central Protocol Data and Monitoring Office (CPDMO). The CT-SRC serves as the final step in a significant, formal, clinical trials concept development process within the SJCCC. The initial responsibility for developing high-quality, appropriately designed clinical trials lies at the level ofthe SJCCC Programs. To this end, each of our Programs that treat patients run clinical trial development efforts that invest great time and effort in protocol development prior to central review. To further enhance the efficient development of clinical trials by the SJCCC Programs, in July of 2012, the CT-SRC implemented a Concept review process for all SJCCC. investigator initiated studies. Additional changes made in the grant cycle period include adoption of a risk-based model for monitoring of clinical trials, formalizing a policy for accruals monitoring by the CT-SRC, and strengthening the committee membership with additional senior researchers. In summary, the SJCRH Protocol Review and Monitoring System evaluates and monitors all prospective clinical trials for scientific merit and alignment with the goals of the SJCCC.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. Jude Children's Research Hospital
United States
Zip Code
Wu, Jianrong (2015) Power and sample size for randomized phase III survival trials under the Weibull model. J Biopharm Stat 25:16-28
Serinagaoglu, Yelda; Paré, Joshua; Giovannini, Marco et al. (2015) Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development. Dev Biol 398:97-109
Kimberg, Cara I; Klosky, James L; Zhang, Nan et al. (2015) Predictors of health care utilization in adult survivors of childhood cancer exposed to central nervous system-directed therapy. Cancer 121:774-82
Bhojwani, Deepa; McCarville, Mary B; Choi, John K et al. (2015) The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. Br J Haematol 168:845-53
Chamdine, Omar; Gaur, Aditya H; Broniscer, Alberto (2015) Effective treatment of cerebral mucormycosis associated with brain surgery. Pediatr Infect Dis J 34:542-3
Karol, Seth E; Coustan-Smith, Elaine; Cao, Xueyuan et al. (2015) Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. Br J Haematol 168:94-101
Chan, W K; Suwannasaen, D; Throm, R E et al. (2015) Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity. Leukemia 29:387-95
Gawade, Prasad L; Oeffinger, Kevin C; Sklar, Charles A et al. (2015) Lifestyle, distress, and pregnancy outcomes in the Childhood Cancer Survivor Study cohort. Am J Obstet Gynecol 212:47.e1-10
Momani, Tha'er G; Mandrell, Belinda N; Gattuso, Jami S et al. (2015) Children's perspective on health-related quality of life during active treatment for acute lymphoblastic leukemia: an advanced content analysis approach. Cancer Nurs 38:49-58
Dodd, K; Nance, S; Quezada, M et al. (2015) Tumor-derived inducible heat-shock protein 70 (HSP70) is an essential component of anti-tumor immunity. Oncogene 34:1312-22

Showing the most recent 10 out of 5513 publications